




PENDING

(IN202211003679)

Ibrutinib loaded liposome formulations and method of preparing the same



NEED

The treatment of chronic lymphocytic leukemia (CLL) using ibrutinib faces challenges like limited bioavailability and adverse effects. Current delivery methods do not fully optimize drug release or targeting.

MARKET ANALYSIS

The global liposomal drug delivery market is expected to grow at a CAGR of 9.2% from 2023 to 2033, driven by the increasing demand for more effective, targeted therapies in oncology and chronic diseases.

TECHNOLOGY OVERVIEW

This technology presents a formulation of ibrutinib-loaded liposomes with improved drug entrapment efficiency (70-95%) and stability. The liposomes are designed to enhance bioavailability, reduce side effects, and enable targeted delivery through modified lipid ratios and cryoprotectant-based lyophilization.

Target Industries

, pharmaceutical manufacturers, drug delivery system developers, biotechnology firms working on cancer therapies, R&D entities focusing on liposomal formulations.

TECHNOLOGY KEY FEATURES

Liposome size: 100-250 nm, high drug entrapment efficiency, zeta potential: -30 to -65 mV, lyophilized formulation, cryoprotectant use (20% trehalose), stability over extended periods.

AT A GLANCE

- SDG 3 (Good Health and Well-being), SDG 9 (Industry, Innovation, and Infrastructure)

[Read more here](#)

Technology is available for licensing/ co-development.

Reach out to Prof. Deepak Chitkara, Coordinator, BITS Technology Enabling Centre,

BITS Pilani Contact Details: tec.bits@pilani.bits-pilani.ac.in, 91 1596-255913

